Metformin for Abdominal Aortic Aneurysm Growth Inhibition

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT04224051

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04224051
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04224051. Randomized; no masking; primary purpose treatment. Start 2020-02-12 (actual); primary completion 2026-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin for Abdominal Aortic Aneurysm Growth Inhibition
Acronym
MAAAGI
Condition
Abdominal Aortic Aneurysm
Intervention (Drug)
Metformin
Intervention (Other)
Standard care
Lead sponsor
Uppsala University Hospital (class: other)

Record details

Record id
cardio:ct-nct04224051
Content hash
bfac773fff484e7483942d6cb7d33efb81a202f4635b4e9f7ea271800269835c